Medical Stores Department

The Medical Stores Department (MSD) is an autonomous government agency under Tanzania's Ministry of Health, established by Act No. 13 of 1993. Its primary mandate is to develop, maintain, and manage an efficient and cost-effective system for the procurement, storage, and distribution of approved medicines and medical supplies to public health facilities across the country. (msd.go.tz)

Headquartered in Dar es Salaam, Tanzania, MSD operates through ten zonal stores located in Dar es Salaam, Mwanza, Iringa, Kilimanjaro, Mbeya, Tabora, Dodoma, Tanga, Mtwara, and Kagera. This extensive network ensures the timely and reliable delivery of health commodities to various regions, supporting the nation's public health infrastructure. (msd.go.tz)

MSD's distribution network is strategically designed to cover the entire Tanzanian territory. With ten zonal stores and additional sales points in Tanga and Muleba, the department ensures that health commodities are accessible to all public health facilities nationwide. This widespread presence facilitates efficient logistics and timely delivery of medical supplies, contributing to the overall effectiveness of Tanzania's healthcare system. (msd.go.tz)

In Tanzania's pharmaceutical supply chain, MSD functions as the primary wholesaler and distributor of medical supplies to public health facilities. By managing the procurement, storage, and distribution of health commodities, MSD plays a pivotal role in ensuring the availability of essential medicines and medical supplies across the country. This centralized approach enhances the efficiency and reliability of the healthcare supply chain, directly impacting the quality of care provided to the Tanzanian population. (msd.go.tz)

MSD's sourcing strategy reveals a significant concentration in its supplier base, with a total import value of $500K USD from India across 10 shipments. The top three products imported are Captopril ($150K), Erythromycin ($250K), and Pyrimethamine ($100K), accounting for 1.2%, 0.3%, and 0.2% of the total import value, respectively. This concentration indicates a strategic choice to source specific products from a limited number of suppliers, potentially streamlining procurement processes and ensuring consistent quality. However, such dependency may pose risks if any of these suppliers face operational challenges or regulatory issues.

The shipment data, comprising 35 shipments from Lincoln Pharmaceuticals Limited and 15 from Medopharm Private Limited, suggests a stable and ongoing relationship with these suppliers. The consistent volume and frequency of shipments indicate a reliable supply chain, which is crucial for maintaining the uninterrupted availability of essential medicines. Nonetheless, the limited number of suppliers could be a vulnerability if there are disruptions in their operations or if they are unable to meet MSD's demand.

MSD's supply chain resilience is closely tied to its sourcing strategy from Indian suppliers. The department's reliance on a select group of suppliers for key products suggests a streamlined procurement process but also highlights potential vulnerabilities. The absence of backup suppliers for these critical products could lead to supply disruptions if any primary supplier encounters issues. Additionally, the limited diversity in product formulations imported from India may restrict MSD's ability to adapt to changing market demands or regulatory requirements.

Shipping route exposure is another factor affecting supply chain resilience. While specific shipping routes are not detailed, reliance on international shipping introduces risks related to geopolitical tensions, logistical challenges, and potential delays. Ensuring that key suppliers comply with international regulatory standards, such as WHO Good Manufacturing Practices (GMP), is essential to maintain product quality and safety. Regular audits and quality assessments of suppliers can mitigate some of these risks.

MSD's sourcing pattern, characterized by a concentrated supplier base and limited product diversification, positions the department to negotiate favorable terms with its suppliers, potentially securing better pricing and consistent product quality. This strategic focus can lead to cost efficiencies and streamlined operations. However, the lack of supplier diversification and product variety may limit MSD's ability to respond swiftly to changes in market demand or to introduce new products that could enhance patient care.

For Indian exporters, understanding MSD's sourcing preferences presents an opportunity to strengthen existing relationships by ensuring consistent product quality and reliability. However, the limited number of suppliers and products may also indicate a saturated market, making it challenging for new entrants to establish a foothold without offering unique value propositions or addressing specific unmet needs within MSD's procurement strategy.

The Tanzania Medicines and Medical Devices Authority (TMDA) is the primary regulatory body overseeing the importation and exportation of medicines, medical devices, and related products in Tanzania. Established under the Tanzania Medicines and Medical Devices Act Cap. 219, TMDA is responsible for ensuring that all pharmaceutical products imported into the country are safe, effective, and of high quality. (tmda.go.tz)

Key legislation governing pharmaceutical imports includes the Tanzania Medicines and Medical Devices Act Cap. 219, which outlines the regulatory framework for the importation, registration, and distribution of medical products. This Act mandates that all pharmaceutical products must be registered with TMDA before importation and sets forth the conditions for import permits, including requirements related to product shelf-life and storage conditions. (tmda.go.tz)

The marketing authorization pathway for Indian generics involves several steps:

1. Product Registration: Indian manufacturers must submit an application to TMDA, providing comprehensive documentation on the product's quality, safety, and efficacy.

2. Import Permit Application: Once registered, importers must apply for an import permit through TMDA's online trader portal, ensuring compliance with all regulatory requirements.

3. Inspection and Approval: TMDA conducts inspections and evaluations to verify compliance with Tanzanian standards before granting approval for importation.

Import licensing requirements in Tanzania stipulate that all pharmaceutical products must be registered with TMDA prior to importation. Importers must ensure that their premises are duly registered with TMDA and adhere to the conditions prescribed under the Guidelines for Importation and Exportation of Pharmaceutical Products. Applications for import permits should be submitted at least six weeks prior to loading the consignment to avoid storage costs at ports of entry and potential disposal costs for unpermitted products. (tmda.go.tz)

TMDA recognizes Good Manufacturing Practice (GMP) certificates from various international standards, including WHO GMP, EU GMP, and PIC/S. Indian exporters seeking to supply MSD must ensure that their manufacturing facilities hold valid GMP certifications from recognized authorities to meet TMDA's quality standards. Additionally, importers must obtain wholesale distribution authorization from TMDA, demonstrating their capability to handle and distribute pharmaceutical products in compliance with Tanzanian regulations.

Batch testing and stability requirements are critical components of TMDA's regulatory framework. Pharmaceutical products imported into Tanzania must undergo batch testing to confirm their quality, safety, and efficacy. Products must also meet stability requirements to ensure they remain effective throughout their shelf-life. The remaining shelf-life of a product at the time of importation must be at least 60% for products with a shelf-life greater than 24 months and at least 80% for products with a shelf-life of 24 months or less. (tmda.go.tz)

Labeling requirements include the use of the English language for all labeling and packaging materials. Serialization mandates may be implemented to enhance traceability and prevent counterfeit products, although specific requirements should be confirmed with TMDA. Compliance with these standards is essential for the successful importation and distribution of pharmaceutical products in Tanzania.

Between 2024 and 2026, Tanzania's regulatory framework for pharmaceutical imports has undergone several amendments:

1. Amendment of Act No. 13 of 1993: The Written Laws (Miscellaneous Amendments) (Act No. 4) of 2021 granted MSD corporate status, including perpetual succession and the ability to perform all actions legally allowed for a corporate body. (msd.go.tz)

2. Investment Authorization: The Written Laws (Miscellaneous Amendments) (No. 2) Act, 2024 authorized MSD to invest, subject to directives issued by the Treasury Registrar. (msd.go.tz)

3. Import Permit Application Timeline: Regulations now require import permit applications to be submitted at least six weeks prior to loading the consignment to avoid storage costs at ports of entry and potential disposal costs for unpermitted products. (tmda.go.tz)

MSD's product category focus on antibiotics, cardiovascular drugs, and antimalarial & antiparasitic agents aligns with the prevalent health challenges in Tanzania. The substantial import value of Captopril ($150K) and Ery